Management of Uncontrolled Anxiety and Behaviors in Dementia

Immediate Assessment and Optimization

The American Academy of Neurology recommends excluding common precipitants that worsen behavioral symptoms, such as delirium from infections or metabolic causes, medication-induced worsening, uncontrolled pain, and environmental stressors, before escalating pharmacotherapy 2
The Alzheimer's Association suggests checking for urinary tract infection, pneumonia, electrolyte abnormalities, and reviewing for anticholinergic medications that could paradoxically worsen cognition and behavior 2
The American Geriatrics Society recommends assessing for sources of discomfort that may manifest as agitation, such as uncontrolled pain 3
The International Psychogeriatric Association suggests recent transitions in residence or care setting may contribute to environmental stressors 4

The American College of Clinical Pharmacology recommends ensuring donepezil is at 10 mg/day, as combination therapy at this dose provides the strongest evidence for managing behavioral symptoms in moderate-to-severe dementia 1
The National Institute on Aging suggests memantine at 20 mg/day provides optimal behavioral control, with significant effects on agitation and neuropsychiatric symptoms 5

The American Academy of Neurology recommends the combination of donepezil plus memantine for patients with moderate-to-severe dementia, as it produces cognitive benefits exceeding the minimum clinically important difference and significant functional benefits over 12 months 1
The Alzheimer's Association describes combination therapy as "rational and safe" for rapid decliners, despite the DOMINO-AD trial finding no significant additional benefits of donepezil-memantine combination over donepezil alone 2, 1

The American Psychiatric Association suggests memantine demonstrates significant protective effects against agitation and improvements in neuropsychiatric symptoms as measured by standardized scales 5
The International Psychogeriatric Association recommends considering discontinuing duloxetine if anxiety symptoms have not improved, as it may contribute to falls risk without clear benefit in this population 3

The American College of Clinical Pharmacology recommends allowing 6-12 months to assess response to optimized combination therapy, with beneficial effects of cholinesterase inhibitors generally observed within 3 months 1
The National Institute on Aging suggests monitoring functional abilities in daily activities, global clinical impression, and specific behavioral scales (NPI, BEHAVE-AD) 3, 4

The American Geriatrics Society recommends considering discontinuing cholinesterase inhibitors or memantine if there is clinically meaningful worsening over 6 months despite treatment, no benefit observed, severe or end-stage dementia, or intolerable side effects 4
The Alzheimer's Association suggests not discontinuing cholinesterase inhibitors in patients with active psychotic symptoms, agitation, or aggression until these symptoms stabilize, unless the medication clearly worsened these symptoms 4

The American College of Clinical Pharmacology recommends ensuring memantine reaches full 20 mg/day unless side effects prevent titration, and avoiding premature discontinuation of medications due to gastrointestinal side effects 1
The National Institute on Aging suggests controlling hypertension, diabetes, and other vascular risks, as these patients may respond better when vascular factors are optimized 2, 1

The American Geriatrics Society recommends tapering gradually by reducing dose 50% every 4 weeks until reaching the initial starting dose, then discontinue after 4 weeks at starting dose, and reinitiate treatment if clinically meaningful worsening occurs that appears related to cessation 4